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  Abstract 
 
 Each year, over 1.6 million people in the U.S. alone will be diagnosed with some 
form of cancer. With advances in treatment, survival rates have risen to nearly 65%.  
While remission and survival are the ultimate goals of treatment, it has become clear that 
many cancer survivors (estimates range from 15% to 70%) treated with chemotherapy 
experience significant, long-lasting cognitive impairment.  This chemotherapy associated 
cognitive impairment is often called "Chemo Fog" or "Chemo Brain." For some, the 
effects are mild, such as having difficulty with focusing, concentrating, and speed of 
processing. For others, the cognitive impairments can be significant and may 
dramatically alter their day-to-day lifestyles, even preventing some from ever returning to 
work.  Growing evidence suggests these impairments are sometimes permanent.  
 The present study attempts to identify the underlying mechanisms of Chemo Fog 
that contribute to impairment in learning, memory and processing speed, associated with 
chemotherapy administration. This study also investigates a potential antidepressant 
treatment that, when co-administered, may reduce the effects of chemotherapy drugs.  
Two proposed explanations as to why such changes follow chemotherapy treatment are; a 
reduction in the proliferation of new brain cells, and a decrease in the myelination of 
axons.  A B6 strain of mice was used as a model for this investigation.  Animals were 
administered the chemotherapy agent 5-Fluorouracil (5-FU) and five a known 
neuroprotectant (fluoxetine) over a period of 5 days. Neural tissue was examined to 
assess the effects of the treatment at 1 day, 14 days and 6 months post-treatment.  A chi-
squared test was used to analyze data from day 1 and day 14 tissue.  A Oneway Anova 
test was used to analyze data from 6-month tissue.  Analysis revealed a significant 
	  reduction in myelin at 1 and 14 days but not 6 months for individuals that received only 
5-FU as compared to controls.  Analysis also showed that animals treated with fluoxetine 
and 5-FU had myelin that was consistent with control animals for short-term time points 
(1+14 days) suggesting myelin preservation.  Statistical tests showed no myelin 
protection for the animals treated with fluoxetine at the 6-month time point as their tissue 
was not statistically different from animals receiving 5-FU alone.
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INTRODUCTION 
  
The issue of pharmacologically induced cognitive impairment associated with the 
administration of chemotherapy is one of great complexity.  For decades, the neurological 
implications of cytotoxic drugs have been largely unknown, and only technological 
advances of the recent years have allowed scientists to begin the arduous process of 
unraveling the intricacies of the biochemical mechanisms involved.  To progress from a 
comprehension of symptoms, to causes, to treatment requires a considerable breadth of 
knowledge, spanning many disciplines of biology, chemistry and psychology.  This paper 
offers an overview of relevant background information, from the pathology of cancer, to 
animal behavioral testing, as well as analysis of research currently being conducted, 
which aims to delineate underlying processes as well as test potentially preventative 
treatments. 
 
1. Cancer 
 
 Cancer, as defined by the National Institute of Health, is a disease in which 
abnormal cells divide rapidly and without control.  These cells can invade other healthy 
tissues by traveling through the lymphatic and circulatory systems.  Cancer is caused by a 
disruption in cellular mechanisms that generally regulate cell replication.  Damage to 
DNA induces mutations that lead to changes in the way a cell functions.  Often these 
mutations are deleterious and result in cell death.  Other times these mutations interfere 
with the process of apoptosis, which is intended or programmed cell death.  When this is 
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the case, cells do not die when they are old, damaged or obstructive.  Instead they 
replicate continuously, forming masses, or tumors.  Evidence suggests that adult stem 
cells in particular play an important role in carcinogenesis (Sell 2004). 
 Cancer is the second leading cause of death in the United States (cdc.gov).  Each 
year, more than 1.6 million people will receive a cancer diagnosis, and the probability of 
an individual developing cancer throughout their lifetime is 40% (cancer.org).  The most 
common forms of cancer are those of the prostate and breast. Although cancer is a 
prominent health concern, national trends are encouraging.  Deaths associated with 
cancer have been declining since 2000 and current survival rates are near 65%.  While 
treatment success is in part attributable to advances in technology, much can be 
accredited to public health education and the avocation of screening and early detection 
for at least some forms of cancer. 
 There are a variety of methods used in the treatment of cancer and often the exact 
regimen is dependent both on the type and location of the cancer, as well as 
characteristics of the patient. However, the most common methods of cancer treatment 
include surgery, radiation therapy or chemotherapy (Seigers et al. 2011).  Frequently, the 
most effective treatments employ a combination of these three strategies.  Most cancer 
treatments involve surgery at some point, particularly when tumorous cells are localized.  
When this is the case, individuals have an increased likelihood of curing their cancer.   
Radiation is the most common form of chemotherapy treatment.  Radiation therapy 
works to damage or destroy cancer cells by exposing them to high levels of energy 
originating from an exterior source, often in the form of x-rays.  This is accomplished 
through damaging portions of the DNA associated with replication.  Radiation affects 
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healthy cells as well, so it is the goal of this therapeutic technique to be as precise as 
possible.  Unlike radiation therapy, chemotherapy works from within the body through 
drugs administered to disrupt cell replication. 
 
2. Chemotherapy 
 
 Roughly one-half of cancer patients receive chemotherapy at some point during 
their treatment.  Chemotherapy is administered intravenously and circulates throughout 
the body. The use of drugs as part of cancer treatment has its origins in the early decades 
of the 20th century (Papac 2002).  The introduction of chemical weapons during the First 
World War provided some unexpected insight into the potentially therapeutic uses of 
mustard gases (sulfuric and nitrogenous).  It was reported that individuals exposed to 
these gases had atrophies of lymphatic, testicular and bone marrow tissues, as determined 
postmortem (Papac 2002).  In addition, cases of mustard gas poisoning produced 
individuals with lower levels of red and white blood cells (Papac 2002).  A subsequent 
study in 1929 revealed that sulfur mustard was “anti-carcinogenic” (Papac 2002).  These 
findings eventually lead to animal, and then clinical testing of nitrogen mustard on the 
suppression of tumors in 1942, the results of which showed unparalleled success.  
Following the incorporation of nitrogen mustard into clinical use, other alkylating 
chemotherapy agents have been developed, but the principals behind many of the current 
chemotherapy drugs have remained the same (Papac 2002).  Contemporary cytostatic 
drugs can be broken up into a number of categories: alkylating agents, platinum-based, 
anthracyclines, and antimetabolites (Seigers et al. 2011). Variation in classification exists 
across different disciplines, however these categories are consistently accepted. 
Regardless of the mechanisms, traditional chemotherapy drugs function to disrupt 
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cellular growth by preventing cell division. 
 
2.1 Alkylating agents:  
 The advent of chemotherapy began with alkylating agents as both nitrogen and 
sulfur mustards fall under this category (Litterman et al, 2013). Alkylating agents work to 
interfere with cellular division by interacting with one or both strands of DNA (Seigers et 
al. 2011).   These drugs induce electron rich atoms to form covalent bonds with a single 
DNA strand in the case of monofunctioning alkylating agents, and cross links between 
the two strands in the case of bifunctioning alkylating agents (Seigers et al. 2011).  
Alkylating agents also result in the methylation of DNA bases (Litterman et al. 2013).  
The cytotoxic consequence results from the accumulation of these DNA lesions and 
while these drugs act non-specifically, they have their greatest anti-neoplastic effects on 
cells that proliferate rapidly (Litterman et al. 2013).  The most well documented 
alkylating agent having effects on cognitive performance is cyclophosphamide (Seigers et 
al. 2011). Cyclophosphamide has been shown to reduce contextual memory and passive 
learning in mice (Seigers et al. 2011). 
 
2.2 Platinum-based agents:   
 Platinum-based chemotherapy agents are often used in the treatment of 
epithelial malignancies including those of the lungs and bladder (Terada et al. 2013).  
Similar to alkylating agents, it is thought that cisplatin and other platinum-based agents 
form both interstrand and intrastrand cross-bridges within cellular DNA (Seigers et al. 
2011).  It is also believed that these drugs induce apoptosis through the disruption of 
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mitochondrial pathways by means of protein activation and increased oxidative stress 
(Terada et al. 2013).  Little has been studied as to cisplatin induced cognitive changes 
(Seigers et al. 2011) 
 
2.3 Anthracyclines:   
 Anthracyclines have a cytotoxic effect by inhibiting topoisomerase enzymes 
(Seigers et al. 2011).  These enzymes are responsible for creating upstream 
conformational changes in unwinding DNA strands to reduce torsional strain resulting 
from supercoiling (Seigers et al. 2011).  Blocking these enzymes results in accumulated 
DNA damage and cessation of replication. Anthracyclines do not readily cross the blood 
brain barrier.  The blood brain barrier is a system within the CNS that works to allow 
only certain substance to cross from the circulatory system into the central nervous 
system.  Typically molecules that are polar, as well as gases, can enter the brain relatively 
easily as they can pass through the polar lipid bilayer of both the capillary walls and the 
assisting astrocytes.  Molecules are precluded from going in between these cells by 
“tight” junctions, a defining feature of the blood brain barrier.  Therefore any molecule 
that is not a gas or is non-polar must be actively transported across these membranes, 
requiring a specific transporting protein to do so.  Without this, molecules have very little 
success exiting the capillaries within the CNS.  Anthracyclines are able to pass into the 
endothelial cells that line the capillaries in the brain, but are not able to go further as they 
are a substrate that is actively transported out of the CNS by p-glycoprotein (P-gp) 
mechanisms (as are many common cytotoxic drugs)(Christie et al. 2012). The most well 
documented anthracycline having cognitive effects is doxorubicin, associated with 
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impaired performance on the novel place recognition task and contextual memory tasks 
in rats (Christie et al. 2012). Doxorubicin is also associated with increased oxidative 
stress. 
 
2.4 Antimetabolites:  
 Chemotherapy drugs of this kind interact with nucleic acids in the DNA 
sequence and interfere with DNA and RNA synthesis (Seigers et al. 2011).  One of two 
most often studied antimetabolites in the context of cognition is 5-FU (Seigers et al. 
2011).  This compound is a pyrimidine analogue (Kareem et al. 2012), meaning its 
structure is similar a class of nucleic acids, pyrimidines.  5-FU works primarily by 
blocking thymidylate synthase, an enzyme responsible for assembling thymidine, a 
crucial molecule for DNA synthesis (Seigers et al. 2011). 5-FU, along with another 
antimetabolite methotrexate, have been shown to reduce performance in spatial MWM as 
well as delayed and non-delayed non-matching to sample learning (Winocur et al. 2006).  
5-FU is one of several drugs that are able to pass through the blood brain barrier with at 
least some degree of success. 5-FU is structurally similar to a molecule that is actively 
transported into the CNS and is therefor able to enter the brain. 
  
Traditional cytostatic drugs are nonspecific and effect cells that proliferate rapidly 
(Littermen et al. 2013), including lymphocytes, epithelial cells lining the gastrointestinal 
tract, and hair cells.  This helps to explain some of the adverse side effects associated 
with chemotherapy.  Nearly all chemotherapy treatment is associated with immune 
suppression in part due to reduced white blood cell production within the bone marrow, 
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but also due to its effects on lymphatic tissues.  Cytostatic agents have been found to 
reduce the magnitude and quality of T and B-lymphocytes to an antigen (Littermen et al. 
2013).  T-cells and B-cells work cooperatively in conjuncture with other facets of the 
immune system to protect the body from foreign substances.  B-cells are referred to as 
signaling lymphocytes, as they produce specific antibodies that mark antigens for 
destruction (Littermen et al. 2013).  T-cells can be differentiated and serve several 
functions, one of which is to destroy antigens marked by antibodies.  These cells 
proliferate in the presence of antigens (Littermen et al. 2013) and a reduction of this 
proliferation as a result of cytostatic drugs would reduce the body's ability to respond to 
external pathogens and viruses. Other common side effects of chemotherapy include 
nausea/vomiting and hair loss, both again in part to the anti-neoplastic mechanisms of 
chemotherapy agents. 
 
3. Chemo-fog 
 In addition to the physical side effects of chemotherapy, cognitive side effects are 
widely reported and well documented.  Clinical research and self-reports suggest that 
anywhere from 15%-75% of individuals receiving chemotherapy treatment experience 
some sort of cognitive impairment (Christie et al. 2012) and that for a subset of those 
effected (17%-34%), impairments are persistent and long lasting (Ahles et al. 2007).  
This phenomenon is often referred to as “chemo-fog” or “chemo-brain” and effects can 
manifest over a range of cognitive functions.  Most commonly affected are the domains 
of working memory, executive functioning, processing speed and attention. Changes in 
these functions are typically mild and do not dramatically interfere with cognitive tasks 
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(Ahles et al. 2007).  In other instances, impairment can be detrimental, substantially 
altering daily function and significantly reducing an individual’s quality of life (Fremouw 
et al. 2011). It is important to note that while working memory is impaired, the retrieval 
of stored memories remains unaffected (Ahles et al. 2007) and that this could provide a 
clue as to the pathways disturbed. The extent to which chemotherapy alone is responsible 
for cognitive changes in cancer survivors continues to be an area of debate, as too are the 
underlying biological mechanisms that could bring about chemotherapy induced 
cognitive alterations (Fremouw et al. 2011).    It is likely that extraneous factors play a 
role in the impairment of cognition for those receiving chemotherapy.  Emotional stresses 
associated with diagnosis, treatment and disease affliction as well as the presence of 
cancer have been suggested to depress cognitive abilities (Fremouw 2011).  Additional 
variables such as genetics, environment and development further confound the origins of 
cognitive decline in cancer patients.  Despite ambiguity in clinical settings, several 
hypotheses have been developed to explain the cognitive effects that may be attributable 
to chemotherapy, and subsequent animal research has begun to shed light on processes 
that have previously been poorly understood. 
 Recent studies as cited by Ahles et al. 2007 have been able to show structural 
changes in the brain that correlate with cognitive impairment in human patients.  
Furthermore these changes appear in areas (such as the prefrontal cortex) that are known 
to mediate the process of working memory as well as structures associated with 
processing speed (white matter) (Ahles et al. 2007).  Functional magnetic resonance 
imaging has allowed researchers to identify decreased activation in associated pathways, 
potentially resulting in an impairment of functions dependent on such structures. 
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Additionally, immunhistochemical staining of post-mortem patient tissue has shown 
damage to areas of the hippocampus following radiation and chemotherapy treatment 
(Monje et al. 2012).  Unfortunately, the same contemporary studies have shown no 
structural abnormalities in subsets of patients that exhibit significant cognitive 
impairment (Monje et al. 2012).  This suggests that more subtle processes must be 
affected that do not necessarily propagate physical alterations but induce a significant 
physiological change.   
 In an attempt to investigate the molecular mechanisms at play in the impairment 
of cognition, a substantial amount of research has utilized a rodent model in experimental 
construction.  By doing so, researchers can avoid many of the confounds associated with 
human subjects as well as the experimental constraints imposed by human testing.  
Rodents allow for the investigation of chemotherapy without the presence of cancer, 
while additionally giving experimenters that ability to control for genetic factors, 
normalize environmental conditions and analyze tissue postmortem at desired time 
points.  The translation between animal research and clinical application is not entirely 
straightforward however.  In humans, much of the cognitive impairment experienced by 
chemotherapy treated patients is associated with changes in cortical regions, while 
research using rats and mice has found the hippocampus as being the major structure that 
mediate the processes of learning and working memory (Evenden 2013).  While less is 
known about the role of the hippocampus in working memory tasks in humans, there is 
some clinical evidence that suggests that it not only play a role in memory consolidation, 
but also in working memory (Squire 1992), in particular the processing of verbal, spatial 
and recognition memory (Mustafa et al. 2008). This has directed much of the focus of 
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animal chemotherapy research to investigate the hippocampus.  In addition to being 
involved in the formation of memories, the hippocampus is a structure of interest because 
it is the site of life long neuronal cell regeneration referred to as neurogenesis. Research 
has identified a population of neuronal stem cells within the hippocampus (specifically 
the denate gyrus) that contribute to the formation and integration of new neurons in this 
location (Monje et al. 2012).  In addition, it is possible migrating neurons developed from 
hippocampal neurogenesis may become integrated in forebrain structures (Monje et al. 
2012). Neurogenesis in the hippocampus seems to be directly related to memory.  Studies 
have shown that animals with decreased neurogenesis perform worse on hippocampal-
mediated tasks and exhibit learning impairment (Seigers et al. 2011). Shor et al. 2001 
demonstrated that a reduction in newly generated neurons leads to impairment on trace 
memory in rats, and that a subsequent recovery in cell production restores performance.  
In addition, animals reared in conditions thought to increase neurogenesis, such as high 
levels of exercise, or an enriched developmental environment exhibit an increased 
capacity for learning (Monje et al .2012).  
 In addition to hippocampal neurogenesis, research suggests that a reduction in 
myelin also contributes to cognitive impairment following chemotherapy treatment.  
Recent studies with breast cancer survivors who received chemotherapy as part of their 
treatment regimen found an association between reported cognitive impairment and 
reduced integrity of myelin structures (de Ruiter et al. 2012).  The role of myelin in 
support of proper cognitive function is further substantiated by literature investigating the 
effects of aging on the brain.  Researchers in Madden et al. 2012 reported that age- 
related decreases in white matter integrity contributes to a reduction in communication 
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efficiency between networks, leading to general impairment in cognitive abilities. 
 In both human and animal studies, there are two methods of assessing the 
cognitive effects of chemotherapy.  One is through behavioral quantification.  In humans, 
this can be administered as a questionnaire to assess changes in cognition, or clinical 
testing in which participants abilities are actively tested.  In animal studies, behavioral 
measures of cognition (particularly those mediated by the hippocampus) are often 
quantified through the administration of tests such as the Morris water navigation test or 
the object location recognition test.   
The second method for detecting the effects of chemotherapy on cognition is through 
the analysis of histological data.  Human studies frequently make use of imaging 
techniques such as FMRI and DTI that allow researchers to externally analyze brain 
structures of interest while patients are still alive.  Comparatively, rodent studies often 
employ methods that apply stains directly to relevant tissue post-mortem.  In this study, 
we utilized two such stains to quantify histological changes in neurogenesis and myelin 
density.  
 
4.  Staining 
As mentioned, research that investigates the phenomena of chemotherapy induced 
cognitive impairment can do so in two ways, behaviorally and histologically.  However 
research is most complete when behavioral changes in the presence of chemotherapy can 
be associated with anatomical changes in the areas of the brain responsible for 
coordinating such processes.  In the case of the present study, two such staining 
techniques were employed to investigate changes in myelin and neurogenesis. 
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         Myelin: There are several different methods of staining myelin, but perhaps the 
most popular and straightforward approach involves the use of gold salt compounds 
(Schmued et al. 2008).  The most contemporary gold based salt compound, and the one 
utilized in this study is Black Gold II.  When dissolved in solution and applied to white 
matter tissue, Black Gold II is taken up by the myelin surrounding axons.  Though it is 
not known why this occurs, the result is a permanent reddish brown staining of axon 
bundles that can be clearly seen under an illuminating field (Schmued et al. 2008). 
        Neurogenesis: In contrast to myelin staining using Black Gold II, the staining for 
neurogenesis is much more time consuming and labor intensive as in involves 
inmmunohistochemical processes.  The most fundamental component of 
immunohistochemistry is the specificity of anti-bodies to antigens.   The process begins 
by isolating a certain protein that you wish to amplify.  In the case of neurogenesis, one 
such protein is Ki67.  Ki67 is a nuclear protein expressed transiently, during the G1, G2 
and S phases of cell division and is therefore an indicator protein of cellular replication.  
Once the protein has been isolated, it is transposed into a host organism (often rabbits are 
used).  The host animal’s immune system recognizes the injected protein as a foreign 
substance, and the subsequent response produces antibodies that are specific to that 
protein.  These antibodies can then be isolated and extracted, and placed back into the 
original animal.  When the induced antibodies are injected into the animal from which the 
antigen originated, these antibodies will bond to those proteins in the animal.  In the case 
of Ki67, antibodies will only bind to cells that are actively dividing, as they are the only 
ones expressing that protein. Once antigens signal the presence of the protein of interest, 
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phosphorescent indicators can be injected.  These indicators have previously been 
engineered to bind to the antibody-signaling molecule, and can be seen using 
phosphorescent scanning technology.  Through this process, it is possible to stain for 
cells that are actively dividing and allow research to observe levels of neurogenesis 
within the hippocampus. 
 
5. Chemotherapy and cognition 
It has been well established that chemotherapy is related to a decline in cognitive 
function for both humans and rodents. Additionally, we have established two different 
methods at identifying these effects.  That being said, to truly justify our motivation for 
this study, it is necessary to further understand the modes by which chemotherapy brings 
about these changes, thus supporting the association between cognitive impairment and 
chemotherapy.  Because chemotherapy drugs are cytotoxic, preferentially targeting cells 
that are actively dividing, it is to be expected that they would have an effect on 
neurogenesis and oligogenesis if given direct access.  Indeed these predictions are 
supported in a number of research studies.  Seigers et al. 2011 found that the 
administration of Methotrexate (MTX) in mice significantly decreased levels of cell 
division in the subgranular zone of the denate gyrus for as long as 3 weeks after 
treatment.  Dietrich et al. found similar results using other common cytotoxic agents, 
increasing cell death in the corpus callosum and denate gyrus up to 10 days after 
treatment, and decreasing cell division up to 6 weeks post treatment.  MTX is a 
chemotherapy agent known to cross the blood brain barrier, however doses used by 
Seigers et al. 2011 (meant to represent those used in adjuvant chemotherapy treatment for 
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breast cancer) are thought to not cross the blood brain barrier successfully. This, 
combined with clinical evidence of cognitive impairment following treatment with 
chemotherapy agents unable to cross the blood brain barrier, and sustained cognitive 
impairment after treatment cessation, suggests that additional mechanisms disrupting 
neurogenesis must be present, other than direct cytotoxic effects.  In addition, cognitive 
impairment is not seen in 100% of patients who receive chemotherapy.  This requires 
further consideration when hypothesizing the underlying mechanisms, taking into 
account genetic variability. 
 
6. Mechanisms 
Despite the accumulation of research over the last several decades, a consensus as to 
the precise mechanisms propagating cognitive change remains elusive.  The most robust 
theories attribute decline to a number of potential mechanisms that interact to cause an 
effect.  Though many chemotherapy drugs have little success crossing the blood brain 
barrier, two common therapeutics agents, 5-FU and methotrexate, appear to be exceptions 
(Ahles et al. 2007).  In the case of these two drugs, it is likely that their main impact 
results from direct anti-mitotic activity, as is their effect systemically.   While other 
chemotherapy drugs commonly used such as cisplatin, BCNU and paclitaxel are not 
thought to pass through the blood brain barrier, positron emission tomography (PET) 
studies have shown low (but detectable) levels of these drugs in the CNS following 
intravenous administration (Ahles et al. 2007).  So, while these drugs are not effective at 
treating tumors within the brain, their presence at low levels may still effect populations 
of dividing neuronal and glial cells (Ahles et al. 2007).  If this is the case, drugs not 
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thought to enter the CNS by the criteria of being ineffective at treating cerebral tumors, 
may in fact be present at very low concentrations, and these concentrations may be 
enough to have direct cytotoxic effects on neurogenesis and oligogenesis.  As mentioned 
before, many common chemotherapy drugs cannot enter the brain as they are substrates 
of the P-gp protein pump, which is responsible for pumping out exotoxins from the 
endothelial cells of the CNS capillaries of the blood brain barrier (Ahles et al. 2007). 
Included among these are cisplatin, BCNU and paclitaxel (Ahles et al. 2007), suggesting 
there must be variability in the effectiveness of this particular efflux protein pump.  In 
fact, several polymorphisms of the gene that codes for the P-gp have been identified, and 
of these, individuals possessing the T allele show lower levels of P-gp expression and are 
more susceptible to long term cognitive impairment (Ahles et al. 2007).  This suggests 
that individuals who have lower levels of P-gp expression are exposed to higher levels of 
chemotherapy drugs not thought to pass the blood brain barrier.  This has been supported 
by animal studies conducted by Muramatsu et al. 2004 in which P-gp deficient mice had 
greater cerebral levels of the chemotherapy agent vincristine following peripheral 
administration as compared to controls.  
While many chemotherapy drugs are designed to cause DNA damage to replicating 
cells as treatment for cancer, they are also associated with increased levels of unbound 
iron, free radicals (H+ protons) and decreased antioxidant activity (Ahles et al. 2007). 
These changes, in addition to exogenous toxins and endogenous metabolic by-products 
increase levels of oxidative stress. Similar to the antimitotic effects of some 
chemotherapy, oxidative stress induces DNA damage through the breaking of single and 
double strand bonds (Ahles et al. 2007).  In addition to bond breakage, oxidative stress 
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(along with chemotherapy and genetic variation) accelerate the shortening of telomeres.  
Telomeres can be thought of as protective caps on the ends of chromatids.  Under normal 
conditions, telomeres are shortened by roughly 20-200 nucleotides following each 
replication (Ahles et al. 2007).  Generally, telomere shortening is believed to play a role 
in the process of aging.  While most neuronal cells do not replicate, and therefor are not 
susceptible to telomere shortening, those involved in neurogenesis and glial genesis 
would be susceptible (Ahles et al. 2007).  The shortening of telomeres offers an 
additional mechanism by which cognition is impaired by chemotherapy as well as a 
candidate mechanism for long-term effects, either by its direct effect on cerebral cell 
telomere length, or by a general acceleration of the aging process.  
Further adding to the variability with which cognition is affected by chemotherapy 
are genetic differences in DNA damage repair mechanisms (Ahles et al. 2007).  It is 
likely that at least a portion of cognitive impairment can be attributed to reduction in 
neural cell proliferation induced by DNA damage.  Polymorphisms in the ability to 
successfully repair DNA damage caused by chemotherapy and oxidative stress, would 
likely lead to some individuals with a reduced capacity to recover from the consequences 
of CNS exposure to cytotoxic drugs (Ahles et al. 2007).  Interestingly, these same 
individuals may have a predisposition to developing cancer in the first place as they 
would also have a reduced ability to repair random DNA mutations that are the initial 
cause of cancer (Ahles et al. 2007).   
A final mechanism by which chemotherapy may impair cognition is by way of 
cytokine deregulation and neuroinflammation.   Cytokines are signaling molecules 
released as part of an immune response, triggered by a number different events, among 
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them DNA damage induced by chemotherapy.  Cytokines play a role in the regulation of 
certain neuronal processes, including glial function, repair, and metabolism of certain 
neurotransmitters (Ahles et al. 2007).  However, deregulated, prolonged elevation of 
cytokine levels is associated with cognitive impairment via neurotoxicity or the induction 
of fatigue and depression (Ahles et al. 2007).  The implications of cytokine mediated 
cognitive decline are crucial for several reasons.  
One, cytokines offer an alternative explanation as to how drugs that are thought to 
not pass through the blood brain barrier still have an effect on cognition.  Though some 
studies suggest that agents other than methotrexate and 5-FU can enter the CNS (Ahles et 
al. 2007), it is possible that they do so in concentrations too low to affect cerebral cell 
proliferation directly.  If this is the case, their effect must originate peripherally.  Ahles et 
al. 2007 suggests that cytokine levels outside of the CNS can have an effect on levels 
within the CNS, either by transport across the blood brain barrier, or through the central 
release of cytokines by way of stimulation of the vagus nerve by peripheral cytokines 
(Ahles et al. 2007).  This suggests that high circulating levels of cytokines as a response 
to chemotherapy induced cell damage in areas outside the CNS, could elevate levels 
within the CNS despite the absence of the agent.  
The second crucial implication of cytokine dependent cognitive decline is the 
potential explanation of long-term cognitive impairment.   DNA damage resulting from 
chemotherapy induces an immune response of cytokine release.  Whether this damage is 
in the CNS or not, communication between peripheral cytokines and central cytokines 
raises levels within and outside the CNS, while creating system-wide inflammation.  
Elevated levels of cytokines within the brain, as well as prolonged neuroinflammation, 
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produce neurotoxic effects on dividing cells directly through glutamate receptor-mediated 
damage or by increasing oxidative stress (Ahles et al. 2007).  These effects further 
increase DNA damage (or initiate if they’re a response to peripheral cell damage) in 
dividing neuronal cells, which in turn sustains centrally elevated cytokine levels even 
after treatment is discontinued. 
Though all aforementioned mechanisms provide potential explanations as to how 
chemotherapy can affect neurogenesis and white matter integrity, it is likely that the true 
process involves a combination of these and others yet to be hypothesized.  A number of 
factors must be taken into account including the type of agent, genetic variations and age 
when considering the overall affect of chemotherapy on cognition as it pertains to 
neurogenesis and oligogenesis. 
 To complete our motivation for this study, we must consider not only how 
chemotherapy affects neurogenesis and myelin integrity in the brain, but also why 
affecting these aspects of cranial anatomy would impair cognition. 
 
7. Neurogenesis and Memory Formation  
Neurogenesis appears necessary for normal hippocampal functioning and certain 
types of memory formation as demonstrated through the use of anti-proliferating agents 
that decrease neurogenesis and cause memory impairment (Mustafa et al. 2008).  Less 
clear however, is the way in which neurogenesis facilitates memory formation.  In the 
mammalian brain, new neurons are continuously incorporated at two locations (Aimone 
et al. 2007).  The first is the olfactory bulb, to which immature neurons born in the sub-
ventricular zone migrate.  These developing neurons integrate locally and serve as 
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interneurons (Aimone et al. 2007).  The second location, the denate gyrus (DG) region of 
the hippocampus, is home to both the origination and integration of new neurons and it is 
this location that is involved in memory formation (Aimone et al. 2007).  Within the 
subgranular zone of the denate gyrus, a population of neuronal progenitor cells divide, 
giving rise to granule cells (GC), which act as the principle neuronal projections of the 
denate gyrus (Aimone et al. 2007, Aasebo et al. 2011).  Granule cells undergo several 
stages of development before being integrated into existing hippocampal circuitry 
(Aimone et al. 2007, Aasebo et al. 2011). The proportion of developing neurons to those 
that make up the denate gyrus is very low however, roughly 3% (Aasebo et al. 2011).  
This further complicates the role of neurogenesis in memory formation, as it is 
counterintuitive to accept that such a small percentage of neurons can have a robust effect 
on memory. To fully understand the function of the denate gyrus and the hippocampus in 
memory formation, it is necessary to reject the notion that these structures are static.  
Instead, these subcortical regions must be viewed as fluid and that their role is dependent 
on the constant addition of maturing neurons. Part of solution lies in unique properties of 
maturing neurons compared to those already incorporated into neuronal pathways.  
Perhaps most importantly among them are the properties of hyperplasticity and 
hyperactivity (Aimone 2007, Aasebo 2011).   
 
Hyperplasticity: Maturing granule cells in the denate gyrus undergo several stages of 
development that are gradient rather than distinct (Aimone et al. 2007). In the rodent 
brain, new neurons do not show dendritic spine arborization and are believed to have 
little effect on information processing during the first week after their birth (Aimone et al. 
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2007).  Aasebo et al. 2011 further support this notion as they found that ablation of 
neurons <7 days of age showed no effect on behavioral measures of memory.  In a period 
that spans the next 14-21 days, maturing granule cells exhibit robust dendritic spine 
arborization as well as mossy axonal projections that begin to synapse with information 
retrieval portions of the hippocampus (ca1 and ca3 regions) (Aimone et al. 2007, Aasebo 
et al. 2011).  It is this period that appears to be key in the function of neurogenesis and 
has thus been labeled the “critical period”.  In addition to rapid arborization, granule cells 
in the critical period show transient expression of NR2B- NMDA glutamate receptors 
(Deng et al. 2010).  This occurs as dendritic projections reach the molecular layer of the 
denate gyrus and are exposed to a glutamanergic environment (Deng 2010).  It is unclear 
whether this glutamate receptor sub-type plays an instructive or permissive role in the 
maturation of neurons, however they are associated with neuronal plasticity during the 
critical period of development.   
 
Hyperactivity:  In addition to the property of hyperplasticity, granule cells in the critical 
period of maturation are also characterized as being hyperactive.  This means that these 
neurons can be induced to show long-term potentiation (LTP) faster and with less input 
than fully mature neurons (Aimone et al. 2007, Aasebo et al. 2011).  This primarily 
comes from the reversed role of GABA receptors in these neurons (Aasebo et al. 2011).  
During the critical period, GABA receptors act in an excitatory role due to the high 
concentration of chloride ions in the young neurons (Aimone et al. 2007) until about the 
third week (Aasebo et al. 2011).  In adult neurons, GABA receptors are inhibitory.  
Generally, neurons are excited through the culmination of thousands of input signals, 
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which can be either excitatory or inhibitory depending on what neurotransmitter is 
released at the synapses, and which receptors are activated.  If incoming signals activate 
more excitatory receptors than inhibitory receptors, an action potential will be generated.  
Because granule cells in the critical period do not have GABA receptors that are 
inhibitory, they will generated an action potential well before an adult neuron receiving 
identical input.  This characteristic is retained even after GABA receptors transition from 
excitatory to inhibitory at around 3 weeks (Deng et al. 2010), due in part because this 
transition coincides with the initiation of glutamate (an excitatory neurotransmitter) 
exposure to dendrites as they reach the molecular layer of the denate gyrus (Deng et al. 
2010). 
 
These properties of young neurons appear to be intimately related to the process of 
memory formation and the encoding of information.  As mentioned previously, certain 
environmental conditions and behaviors are thought to increase neurogenesis and 
improve dependent memory functions. Initially, experience and information processing 
appear to support maturing neurons and distinguish those that will survive to be 
incorporated, from those that die off (Aasebo et al. 2011). This is thought to be mediated 
through the activation of the NMDA- glutamate receptors, which then propagate further 
glutamate synapse and dendrite spine formation within activated neurons (Aasebo et al. 
2011).  The notion that experience and information input regulate the maturation of 
neurons helps to explain not only why proper memory formation requires the survival of 
only some new neurons, but also how new neurons facilitate this process. 
 The exact process by which the hippocampus encodes memories and the role of 
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the denate gyrus/neurogenesis in this process is still up for debate.  One potential factor 
could be the location of the denate gyrus in relation to hippocampal pathways (Deng et al. 
2010).  Traditionally, the denate gyrus is considered the “gateway to the hippocampus, 
receiving informational from the entorhinal cortex and sending projections to the Ca3 
region of the hippocampus (Deng et al. 2010).  What remains to be discovered is the role 
neurogenesis plays at this memory formation switchboard.  Aimone et al. 2007 proposes 
that two processes, pattern separation and pattern integration facilitate the proper 
encoding of events.  Pattern separation, suggests Aimone, results from the relatively few 
number of neurons in the denate gyrus that are activated for any one given experience.  
Statistically, the likelihood that these same neurons would be activated for a following 
event is low, providing an anatomical basis for the separation of events as a function of 
time.  This is not an intrinsic property of granule cells in the critical period, but a general 
function of adult neurons in the denate gyrus.  According to Aimone et al. 2007, young 
neurons assist in the formation of memories by providing pattern integration.  Due to 
their hyperactive property, new neurons preferentially respond to incoming stimuli 
(Aimone et al. 2007) and it is therefore more likely that a single new neuron can be 
activated by different events. Young granule cells do not dominate this response 
however, as they still represent only a small portion of the denate gyrus neuronal 
population, preserving the pattern separation effect.  In combination, these two processes 
simultaneously allow for the ability to distinguish events, yet associate them.  Incoming 
information activates mature neurons discretely, with each new event activating distinct 
mature populations.  Simultaneously, each event activates the same population of highly 
excitable granule cells that are in their critical period.  All this encoded information is 
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sent downstream to the ca1 and ca3 retrieval locations of the hippocampus.  
 In addition to pattern integration, critical period neurons also assist in pattern 
separation (Aimone et al. 2007, Aasebo et al. 2011).  One proposed mechanism is that 
waves of new neurons incorporate incoming information as they develop (Aimone et al. 
2007).  As they reach adulthood, they lose this hyperactive property, and a new wave of 
critical period granule cells replaces them. Thereby, events occurring on the same day are 
all encoded by a common population of critical period neurons, but events separated by 
several days are encoded by two distinct populations of immature neurons (Aimone et al. 
2007). 
 While a significant portion of immature neurons successfully develop and become 
incorporated within the neuronal circuitry, a percentage of them die off (Aimone et al. 
2007). Enriched environments increase the rates of survivability of developing neurons 
by activating a greater proportion of them.  It is in this way that greater experience 
increases neurogenesis, and neurogenesis facilitates the encoding of these experiences. 
 With the survival and integration of a large portion of immature neurons, the 
question then becomes of their long-term function and the consequence of continuous 
addition of new neurons to the already existing circuitry.  While granule cells born of 
postnatal neurogenesis closely resemble mature neurons of the denate gyrus by 8 weeks 
of age, they still retain a distinct and elevated level of plasticity as late as 6 weeks after 
birth (Aimone et al. 2007, Deng et al. 2010).  This property leads to the conclusion that 
neurogenesis facilitate the formation of new memories by providing neurons that are not 
completely specific to older memories, and thus available to encode new information 
(Aimone et al. 2007).  Current studies suggest that new neurons do not simply replace old 
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ones, which would require that new information replace old information (Aimone et al. 
2007, Aasebo et al. 2011).  Instead, maturing neurons are additively integrated into 
hippocampal pathways (Aimone et al. 2007).  This model of neurogenesis integration has 
two important implications.  First, the formation of new memories, as facilitated by adult 
born granule cells, prevents the destruction of old memories to make way for the 
encoding of new information (Aimone et al. 2007).  It also prevents an overload of 
information that theoretically could occur if additional information was encoded by the 
denate gyrus without the addition of new neurons, or with a systematic addition and 
deletion model of integration (Aimone et al. 2007). 
 The second implication proposed by Aimone et al. 2007 through their 
computational model, is that immature neurons that are integrated into the hippocampal 
circuitry as they encode new information may be activated preferentially by the same 
information in the future.  This provides a long-term function for neurons originating 
from postnatal neurogenesis.  If young neurons are specialized, or imprinted with certain 
events as they are integrated, than exposure to the same stimuli at a later point in time 
may utilize these already integrated pathways.  Doing so may streamline the processing 
of the hippocampus, increasing the efficiency of memory encoding. 
 
8. Oligodendrocytes and Oligogenesis 
Neurogenesis in the hippocampus offers not only an explanation as to the formation 
of new memories, but it also allows for a reasonable hypothesis as to how chemotherapy 
could impair memory.  However, survivors receiving chemotherapy also report issues 
with processing speed and attention.  To tackle the cause of these impairments, it 
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becomes necessary to investigate another process likely disrupted by chemotherapeutic 
agents. 
 In addition to neurons, progenitor cells in subcortical areas of the brain also give 
rise to another class of CNS cells.  These ‘support’ cells are known as glial cells, and can 
be further delineated according to their function. Perhaps of most relevance to the process 
of cognition are oligodendrocyte glial cells.  These cells are responsible for encapsulating 
neurons of the central nervous system in a myelin sheath.  Due to the high lipid content of 
myelin, it serves to increase the speed at which electrical signals are propagated down the 
length of an axon. This is thought to allow information processing to occur normally, and 
subsequent damage to myelin would likely decrease processing speed. In addition, the 
lipid component of myelin gives axons a white appearance. Within the CNS, white matter 
therefor reflects areas that consist of mostly myelinated axons.  At birth, large portions of 
the CNS remain unmyelinated (Catts et al., 2013), however by early adulthood, it is 
believed that a majority of neuronal myelination has occurred. That being said, 
oligodendrocyte genesis continues throughout life in both cortical and subcortical areas. 
The role of newly derived oligodendrocytes may be to either myelinate neurons for the 
first time, or repair damaged myelin in both the brain and spinal cord (Mctigue et al. 
1998). Because these cells are continuously produced throughout adulthood, they are also 
susceptible to the effects of chemotherapy due their proliferative characteristic. 
 Chemotherapy has been shown to affect the levels of myelin, specifically in the 
Corpus Callosum (Seigers et al. 2011).  In addition these changes have been associated 
with decreased myelinating cells and oligodendrocyte precursor cell expression following 
treatment with 5-FU in rats (Han et al. 2008).   While decreased expression of the 
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precursor cells suggest that cognitive impairments are a result of a reduction in new glial 
cell production, research also indicates that the functionality of adult oligodendrocytes 
may also be impaired (Dietrich et al. 2008).  In one study, Dietrich et al. 2008 
investigated whether 5-FU had an effect on adult oligodendrocytes in the corpus 
callosum.  This was achieved through marking and labeling of Olig2, myelin basic 
protein (MBP) and CC1, all proteins expressed by functional myelinating cells.  
Researchers found a significant reduction in the expression of Olig2 and MBP 56 days 
after treatment in animals that received 5-FU.  Expression of CC1 protein was consistent 
between the control and chemotherapy groups at day 56.  This suggests that there was not 
a reduction in the amount of adult oligodendrocytes, but there was a significant 
impairment in their function.   In addition to somewhat long-term effects suggested by 
Dietrich et al. 2008, short-term effects of chemotherapy on myelin have also been 
documented.  Researchers in Han et al. 2008 suggested the presence of myelin damage 14 
days following chemotherapy treatment through the use of auditory brain response 
(ABR) analysis.  ABR is a technique that measures the latency of auditory information 
signaling.  Increased latency in auditory processing indicates damage to myelin tracts in 
auditory pathways (Ito et al., 2004).    In accordance with Hans et al. 2008, unpublished 
results from our lab suggest the presence of myelin damage following treatment with 5-
FU 1 day and 14 days after administration as indicated by ABR. 
Animal literature has also shown pharmacologically induced myelin damage to 
negatively impact cognition.  In studies that replicate myelin damage seen with multiple 
sclerosis, researchers have found impairments in spatial learning and memory in rats at 
both long term (90 days) and short-term time points (Xiao et al. 2008, D’Intino et al. 
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2005). 
This animal data supports clinical studies in which neuroimaging has shown 
decreased amounts of white matter in patients following chemotherapy treatment (Ahles 
et al. 2007). In addition, it is also well documented that lesions to white matter areas of 
the brain have a negative impact on cognition (Frisoni et al., 2007).  These observations 
of white matter damage can also be correlated with self-reported impairment in attention 
and processing speed.  In a study by Deprez et al. (2011) researchers found that reports of 
cognitive impairment by patients 3-6 months after chemotherapy treatment, negatively 
correlated with white matter integrity as determined using diffusion tensor imaging 
(DTI).  DTI is a technique that measures the ability of water molecules to diffuse into 
white matter tissue.  The directionality of this movement is quantified using Fractional 
Anisotropy, and the highest FA values are recorded when white matter is healthy 
(Madden et al. 2012).  Additionally, reports of more severe symptoms were associated 
with the identification of more widespread white matter damage. 
Research into the effects of aging on cognition support the notion that white matter 
integrity is associated with cognitive performance.  In studies that investigate white 
matter changes as people age, researchers have found that cognitive decline associated 
with both normal aging and disorders such as dementia, is often congruent with 
microstructural decreases in white matter integrity (Vernooji et al., 2009).  Furthermore, 
Bucur et al. 2008 was able to demonstrate that reduced processing speed resulting from 
white matter damage in the corpus callosum and pericallosal frontal cortex was initially 
mediating the impairment of explicit memory retrieval, rather than aging effects.  As a 
whole, the human literature suggests that (i) cognitive decline, such as that associated 
	   28 
with aging, is at least in part mediated by reduction in white matter integrity and (ii) 
changes in white matter can be induced by processes other than aging (such as 
chemotherapy). 
 
9. Neuroprotectants 
Much of the recent research surrounding chemotherapy and cognitive impairment has 
focused on developing an understanding of the biochemical mechanisms responsible for 
inducing histological changes in the brain, and how these changes would lead to 
cognitive decline.  However, some studies have also investigated potential treatments that 
could help alleviate cognitive symptoms.  Seigers et al. 2011 reviews a host of potential 
remedies that each address a proposed mechanism.  Among them are; treatment with 
antioxidants that reduce the effects of oxidative stress, administration of steroids to 
mediate the effects of pro-inflammatory cytokine release, an exercise, which is thought to 
have widespread beneficial effects. 
 In addition to those treatments mentioned above, some studies have investigated 
the potential of selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine to 
mitigate chemotherapy induced cognitive decline, as serotonin is one of several 
neurotransmitters that appear to influence cognitive function (Seigers et al. 2011).  A 
study in which Madhyastha et al. 2002 administered methotrexate to mice, found lower 
levels of dopamine, norepinephrine and serotonin in the hippocampus and that these 
changes were associated with cognitive impairment by way of conditioned avoidance 
task. 
 By administering a reuptake inhibitor like fluoxetine, it is possible to induce 
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greater extracellular concentrations of neurotransmitters.  This is achieved by fluoxetine 
via noncompetitive inhibition.  Normally when a neurotransmitter is released into the 
synaptic cleft from the presynaptic membrane, excess neurotransmitter is pumped back 
into the presynaptic cell by transporter proteins.  Inhibitors like fluoxetine bind to an 
allosteric site on these transporters, inducing a conformational change in the protein, thus 
lowering its affinity for the neurotransmitter and preventing their proper transport back 
into the presynaptic neuron.  
Though the mechanisms are not entirely understood, studies indicate that 
administration of fluoxetine and other SSRI’s results in increases levels of neural cell 
genesis (Surget et al. 2011).  While these studies often investigate the function of 
antidepressants in the context of depression, their effect on neurogenesis and oligogenesis 
supports the notion that they may be useful in treating cognitive impairment partially 
caused by a reduction in neuronal cell proliferation. 
 
To review, the objectives of the present study are;  (i) to replicate the reduction of 
neurogenesis and white matter integrity through the administration of the chemotherapy 
agent 5-FU, (ii) to show that these changes are not only acute, but persist well after 
treatment cessation, and (iii) identify if the antidepressant drug Fluoxetine (a SSRI) can 
prevent or reduce cognitive impairment when co-administered.  Contemporary research 
across many disciplines provides motivation for the goals of this study.  There is a host of 
literature to suggest that chemotherapy has negative effects on tissue in the brain, 
particularly on proliferating cells in the hippocampus and the integrity of white matter in 
the corpus callosum.  In addition, there is significant evidence that indicates these two 
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aspects of cranial anatomy mediate working memory and normal processing speed 
respectively.  Finally, while investigation into potential remedies is novel, there is 
evidence to suggest that certain substances that are known to increase cell proliferation 
may be used to prevent or mitigate the negative effects of chemotherapy on cognition.  
To accomplish these goals, animals will be subject to three separate conditions.  The first 
will consist of animals that will receive only saline treatment.  This provides a control to 
which the other groups can be compared.  The second group will include animals that 
only receive 5-FU injections.  The final group will consist of animals who receive both 5-
FU and fluoxetine treatment.  The two experimental groups allow for the study to 
independently investigate the effects of only chemotherapy, and the effects of 
chemotherapy in the presence of a neuroprotectant.   
 
 
 
METHODS 
 
1. Animals 
 
Sixty male C57BL/6J mice were obtained from Jackson Laboratories in Bar Harbor, 
Maine.  Animals were housed four or five to a cage and given access to food and water at 
their discretion.  A twelve-hour light dark cycle (7:30 A.M. – 7:30 P.M.) was used for the 
duration of the experiment.  Animals were routinely weighed as well as checked for teeth 
and coat quality.  All experiments were approved by the Institutional Animal Care and 
Use Committee (IACUC) at the University of Maine and conducted in accordance with 
“The Principals of Laboratory Animal Use and Care” (NIH publication No. 86–23, 
revised 1985). 
 
	   31 
2. Treatments 
 
All mice began treatment at approximately 10-11 weeks of age.  Mice were assigned 
randomly to 1 of 3 conditions: Control, 5-FU, or 5-FU + Fluoxetine.   Because increases 
in cell proliferation via fluoxetine administration take 2-3 weeks to occur, mice in the 5-
FU + Fluoxetine group underwent a pretreatment period for 21 days during which 
fluoxetine was administered via their drinking water (attempted dose: 16mg/kg).   Actual 
dose as assessed by weighing the water bottles every three days varied between 12 and 15 
mg/kg.  Following the pretreatment period, animals were given a total of 3 intraperitoneal 
injections (an injection every other day for 5 days) of either the chemotherapy agent (5-
Fluorouracil) or saline as a control as depicted in Figure.  In addition, the 5-FU + 
Fluoxetine animals received neuroprotectant injection (fluoxetine) every day over that 
five day period.  The control and 5-FU animals received an injection of saline every day 
over that five day period as a control for the 5 injections of fluoxetine that the 5-FU + 
Fluoxetine animals received in addition to their 3 injections of 5-FU. Concentrations and 
dosages are displayed below.  The chemotherapy and neuroprotectant agents were 
dissolved in 0.9% saline. 
 
Intraperitoneal injections  
Saline (0.9%) + Saline (0.9%)  
5-fluorouracil (70 mg/kg) + Saline (0.9%)  
5-fluorouracil (70mg/kg) + Fluoxetine (12mg/kg) 
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Administration Schedule 
 
 
 
 
            Figure 1. 
 
 
3. Slicing 
 
At 1 and 14 days and 6 months following the cessation of treatment, animals from 
each condition were transcardially perfused with 4% paraformaldehyde (PFA).  Brains 
were removed from the animals and placed in a PFA solution followed by a 30% sucrose 
solution, before being flash frozen.  Tissue was kept in freezers until they were ready to 
be sliced.  40-micrometer coronal sections were sliced, starting at the anterior of the 
cortex.  Slices were placed in a potassium phosphate buffer saline solution and later 
transferred to an antifreeze cryoprotectant solution and stored at -20 F. 
 
4. Myelin Staining 
 
Staining began by mounting tissue on a series on slides, with each slide containing a 
brain from five different conditions (Saline, 5-FU, 5-FU + Fluoxetine and 5-FU + two 
other neuroprotectants not included in the scope of this study.  Slides were mounted using 
a .0125% potassium phosphate buffer solution to float the tissue into position and then 
left to dry.  Slides were chosen based on their position (anterior – posterior) by 
	   33 
identifying where the Corpus Callosum first came together, and then choosing the 4th 
slide following in that series.  The position of the tissue from each condition was rotated 
for each of the slides prepared. 
Slides were rehydrated through a series of washes (30% ethanol and double distilled 
water for two minutes each) before being placed in a black gold II solution heated to 63 
degrees centigrade.  Tissue was submerged in the BGII solution for 8-10 minutes, with 
periodic monitoring of stain uptake and quality.  Following the BGII solution, slides were 
again washed starting with double distilled water (2min), a thiosulfate solution (3 min), 
tap water (3 times, 5 min each), 70% ethanol solution (2.5 minutes), 95% ethanol solution 
(2.5 minutes), 100% ethanol solution (2x 2.5 min) and Histoclear for 5 minutes. Cover 
slips were mounted using paramount gel and slides were left to air-dry. 
 
5. Images and Rating 
After slides were thoroughly air-dried, images of each brain were taken using camera-
mounted Zeiss Axio Imager Z1 microscope, with 400x magnification.  The specific 
location of images focused on the lateral corpus callosum at consistent anterior/posterior 
locations as indicated by figure 2.  This location was chosen for two reasons.  First, the 
corpus callosum is a widely accepted model of global myelin health.  Secondly, more 
medial sections of the corpus callosum have a tendency to curl up during staining, 
resulting in an inflation of myelin density in this region.  Rating of short term and long-
term data was conducted separately, using different rating techniques, as damage 
occurring in tissue collected shortly following treatment was distinctly unique than in 
tissue collected 6 months post treatment.  ImageJ rating software was used to analyze 
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tissue from the 6-month conditions.  This analysis works through calculating the intensity 
of each pixel in the image.  Pixels are rated on a 0-256 scale following the conversion to 
a grey scale, with 0 being black and 256 being white.  The median value for all pixels in 
the image was calculated and coding was inverted (intensity value was subtracted from 
256) to make it so that more myelin was represented by higher values and less myelin by 
lower values.  Figure 3. Illustrates different myelin densities increasing from image A-D.  
Tissue from days 1 and 14 exhibited myelin damage that was not conducive to 
analysis by ImageJ software.  Damage from these two time points manifested as missing 
fibers rather than the widespread decrease in density as seen at 6 months.  If ImageJ were 
used, areas of white created by missing tissue would have impacted results.  Given this, a 
different method for tissue analysis was required.  Instead of rating tissue on a density 
scale, tissue was identified as either having significant myelin damage or not having 
significant myelin damage, based on the degree of missing fibers.  Figure 4 depicts tissue 
with myelin damage and figure 5 depicts tissue with no myelin damage. 
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      Figure 2. 
 
 
     Figure 3. 
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        Figure 4.          Figure 5. 
 
 
 
 
 
 
 
 
RESULTS 
 
 
As seen in Figure 6, myelin damage at day 1 was rare in the control and 5-FU + 
fluoxetine groups, but fairly common in the 5-FU group.  
Day 1 data: 
 
 
Figure 6. 
 
 
Condition  No myelin damage Myelin damage 
Control 
 
6 0 
5-fluorouracil 3 4 
5-fluorouracil + 
fluoxetine 
6 1 
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A chi-square test indicated that the groups did differ χ2 (2, N = 20) = 6.29, p < 
0.05. Follow-up testing Further analysis revealed this difference to be between the control 
group and 5-FU groups χ2 (1, N = 13) = 4.95, p < 0.05. This statistical analysis shows 
significantly more animals in the 5-FU condition had tissue that exhibited myelin damage 
as compared to the control group 1 day following treatment. 
 As seen in Figure 2, myelin damage at day 14 was rare in the control and 5-FU + 
fluoxetine groups, but common in the 5-FU group. 
 
 
Day 14 data: 
 
 
Figure 7. 
A chi-square test indicated that the groups did not differ χ2 (2, N = 19) = 4.25, p = 0.12.   
Because our main hypothesis was that the control and 5-FU groups would differ, we 
compared those two groups directly as well.  A chi-square test indicated that more 
animals given 5-FU showed tissue indicative of myelin damage than the control animals 
χ2 (2, N = 13) = 3.90, p < 0.05.   
Condition No myelin damage Myelin damage 
Control 5 1 
5-fluorouracil 2 5 
5-fluorouracil + 
fluoxetine 
4 2 
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 Given the relative symmetry of the day 1 and day 14 data, these sets were 
combined to increase statistical power.  Figure 3 shows the combined Day 1 and Day 14 
data. 
 
 
Day 1 and 14 combined data:  
        
    Figure 8 
A chi-square test indicated that the groups did differ χ2 (2, N = 39) = 10.03, p < 0.01. 
Further analysis revealed more animals in the 5-FU condition had tissue that exhibited 
myelin damage than the control group χ2 (1, N = 26) = 8.55, p < 0.005..  Interestingly, 
further analysis also revealed that more animals in the 5-FU condition had tissue that 
exhibited myelin damage than the group that received 5-FU + fluoxetine χ2 (1, N = 27) = 
4.64, p < 0.05.    
 
 
 
 
 
 
 
 
Condition No myelin damage Myelin damage 
Control 11 1 
5-fluorouracil 5 9 
5-fluorouracil + 
fluoxetine 
10 3 
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6 Month data: 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Figure 9. 
  
A Oneway Anova of the data from figure 9 indicated that the groups did not differ in 
myelin density:  F2, 19  = .262 N = 21 p = .722  
 
 
 
 
 
DISCUSSION 
 
 
 The goals of this study were to investigate the effects of the chemotherapy agent 
5-FU on neurogenesis and white matter integrity at both short term and long-term time 
points.  In addition, this study aimed to test the effectiveness of the proliferating agent 
fluoxetine, at preventing chemotherapy-induced changes in the hippocampus and corpus 
callosum. 
 
 
Condition Median Density  
Control  77.00 +/-  3.4 
5-fluorouracil 68.375 +/-  10.5 
5-fluorouracil + 
fluoxetine 
78.429  +/-  15.85 
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1. Myelin 
The results indicate that the administration of 5-FU significantly decreased the 
integrity of white matter tissue in the corpus callosum at both 1 and 14 days post 
treatment as compared to controls.  This is consistent with findings by Seigers et al. 2011 
in which researchers identified decreased white matter thickness in the lateral corpus 
callosum in mice following methotrexate administration at one day, one week and three 
weeks post treatment.  These decreases, along with decreases in neurogenesis, were 
associated with decreased cognitive performance at one week and four weeks post 
treatment. 
These results may be indicative of either a reduction in new glial cell production, 
or damage to existing myelinating cells in the corpus callosum.  Previous research by 
Han et al. 2008 has shown that 5-FU affects not only progenitor cells in the CNS, but also 
non-dividing oligodendrocytes.  Results from this study indicated a significant reduction 
in progenitor cells as well as a possible increase in cell apoptosis in the corpus callosum 
one day following treatment.  This study also showed a delayed effect of 5-FU.  At 56 
days post treatment, researchers identified a reduction not only in cell proliferation, but 
also a reduction in oligodendrocytes that produce protein Olig2+ (present in normal 
functioning oligodendrocytes), however there was no cell apoptosis present at this time 
point. 
Our short-term results fit the observations by Han et al. 2008 concerning the types 
of damage seen in the corpus callosum.  Previous research indicates that apoptosis may 
be present shortly after treatment but is absent at long term time points.  Our staining and 
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analysis indicate a significant difference in the degree of fibers present shortly following 
chemotherapy for control animals and those receiving 5-FU. Given the loss of fibers, our 
data suggests that short-term myelin damage in the corpus callosum may be a result of 
oligodendrocyte apoptosis and a reduction in progenitor cell proliferation. 
Our short-term data also indicates the fluoxetine may be effective at preventing 
myelin damage in the corpus callosum when co-administered.  Animals that received 
both fluoxetine and 5-FU exhibited myelin that was similar to controls.  Because 
fluoxetine is a proliferating agent, administering it concurrently with a chemotherapy 
drug may at least compensate for the decrease in oligogenesis.  That being said, there is 
no literature that suggests proliferating agents would be effective in preventing cell 
apoptosis.  
Results of data from tissue 6 months following treatment was unsuccessful in 
showing significant effects of 5-FU on white matter integrity in the corpus callosum.  
Animals from all three conditions showed similar levels of myelin density as determined 
by both imaging software and researcher ratings.  This data would seemingly oppose 
other contemporary studies in which researchers suggested there to by myelin damage in 
the corpus callosum 6 months following chemotherapy treatment (Han et al. 2008).  
However, unpublished data from our lab indicates animals that received 5-FU exhibited 
significant decreases in myelin density 14 months following treatment.  Furthermore, the 
levels of myelin density for animals 14 months following 5-FU injection were similar to 
the myelin density levels of 5-FU animals and 5-FU + fluoxetine animals 6 months 
following injection.   
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If we assume that levels of myelin density 6 months following treatment, for 
animals receiving 5-FU in this study are indicative of white matter integrity reduction (as 
values are consistent with chemotherapy-induced damage in other lab conditions), we can 
proceed cautiously with an analysis of long term results from this study that are 
consistent with contemporary literature.   
Unlike tissue from short-term time points, tissue from the 6 months post treatment 
animals was quantified only by the density of black gold II stain (rather than degree of 
fibers), as there was no apparent difference in the amount of myelinated fibers present. 
Results indicate that both animals receiving 5-FU alone, and those receiving 5-FU and 
fluoxetine had reduced myelin density in the corpus callosum when compared to controls 
outside the condition.  While short-term effects of chemotherapy seem to indicate 
chemotherapy-induced apoptosis and a reduction in proliferation, 6-month data indicates 
either a continued reduction in cell proliferation, a reduction in the amount of mature 
oligodendrocytes that are functioning properly, or both.  Consistent levels of fibers across 
conditions at this time point suggest an absence of apoptosis, consistent with findings 
from Han et al.  2008.  Interestingly, these results indicate that fluoxetine was not 
effective at preventing myelin damage induced by 5-FU 6 months following treatment. 
Results from both the short term and long term data in this study suggest 
discrepancies in the way 5-FU effects white matter tissue in the corpus callosum over 
time.  Tissue from animals treated with 5-FU collected shortly following the cessation of 
treatment exhibited a reduction in the amount of fibers present in the corpus callosum, 
where tissue collected from animals 6 months following treatment showed no difference 
in the amount of fibers present, but instead exhibited a reduction in myelin density.  
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While these results indicate that 5-FU has both acute and prolonged effects on white 
matter integrity, it also suggests that distinct processes contribute to each. 
Given the reduction of fibers seen in 5-FU animals shortly following treatment 
and supporting research by Han et al. 2008, we can tentatively conclude that at least some 
of the myelin damage at this time point is indicative of oligodendrocyte apoptosis.  It is 
more difficult to conclude the type of oligodendrocyte that is affected.  Because apoptosis 
is not thought to occur well after stopping treatment, and we do not see a difference in the 
amount of fibers 6 months post treatment, it would appear that the reduction in fibers 
shortly following chemotherapy administration is a consequence of apoptosis.  However, 
our results indicate that the presence of fluoxetine prevents a reduction in fibers caused 
by 5-FU shortly following treatment.  Because fluoxetine is a proliferating agent, you 
would expect it to prevent myelin damage by increasing oligogenesis.  If the reduction of 
fibers by 5-FU is a result of apoptosis targeting proliferative oligodendrocyte precursor 
cells, we would expect that concurrent fluoxetine administration would counteract this 
effect, thereby eliminating fiber reduction in the corpus callosum following 
chemotherapy treatment.  This is not contradictory to our results that show no effect of 
fluoxetine 6 months following treatment.  The reason for this calls upon the proposed 
mechanisms of the long-term effects of chemotherapy on cognition.  Recall that 
chemotherapy administration is thought to increase neuroinflammation, oxidative stress 
and CNS cytokine levels.  If levels of any of these remained high following the cessation 
of both chemotherapy and neuroprotectant treatment, you would expect unabated 
decreases in oligogenesis, resulting in prolonged reduction in white matter integrity. 
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What is difficult to explain is the absence of fiber reduction 6 months following 
chemotherapy administration.  One possible explanation is that 5-FU induces apoptosis of 
both progenitor cells and adult oligodendrocytes.  This would be surprising as 5-FU is 
thought to target only proliferating cells, however previous research shows that even non-
dividing oligodendrocytes are susceptible to apoptosis induced by 5-FU, though it is not 
clear why (Han et al. 2008). If this were the case, not only would the administration of 
chemotherapy kill entire cells that are myelinating axons but it would also reduce the 
ability to replace these cells.  Short-term tissue may reflect this through an absence of 
fibers since adult oligodendrocyte death could leave some axons completely 
unmyelinated.  Fluoxetine could potentially mitigate this effect if it were to counteract the 
antiproliferating effects of 5-FU and hold oligogenesis rates normal, thereby replacing the 
apoptotic adult oligodendrocytes as they died.   Following the initial wave of adult 
oligodendrocyte death initiated directly by 5-FU, it is possible that subsequent 
oligogenesis would preferentially myelinate those axons that were completely stripped.  
This may explain why there does not appear to be a reduction of fibers 6 months 
following 5-FU administration, but only a reduction in myelin density.  Because 
chemotherapy exposure is thought to initiate antineogenic processes that continue after 
treatment is stopped, levels of oligogenesis may remain low following only 
chemotherapy administration, and drop once treatment with fluoxetine was discontinued.  
The myelin around a single axon is not static over time.  As with most tissue in the body, 
it eventually breaks down and needs replacing.  It is believed that one role of oligogenesis 
is to replace myelin that breaks down naturally. Research suggests that following 
chemotherapy; levels of oligogenesis remain suppressed as a result of 
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neuroinflammation.  If this were the case, you would expect to see less myelin repair of 
the normal breakdown of myelin well after the cessation of chemotherapy treatment, and 
that decreased myelin density would be a reflection of this process. 
Regardless of the exact mechanisms by which 5-FU acted to induce myelin 
damage, these results suggest that systematic administration of 5-FU decreases the 
quality of myelin in the corpus callosum at both acute and prolonged time points.  This 
study, in conjuncture with research affirming the necessity of healthy myelin for normal 
information processing, strongly supports the hypothesis that some symptoms (both acute 
and persistent) of cognitive impairment following chemotherapy are a result of myelin 
damage in the CNS.  In addition, this study confirms the possibility that the co-
administration of the antidepressant drug fluoxetine may help to prevent acute cognitive 
impairment caused by myelin reduction. 
 
2. Neurogenesis and the Hippocampus 
  
 The assessment of neurogenesis in the hippocampus following 5-FU 
administration was a goal of this study for several reasons. First, the production of new 
neurons in the hippocampus has been linked to the process of memory formation. 
Secondly, memory impairment is not only one of the most pervasive cognitive symptoms 
experienced by chemotherapy patients shortly following and well after treatment, but 
ablation of hippocampal neurogenesis in animal research has consistently resulted in 
declined performance on hippocampal mediated memory tasks.  Finally, given the nature 
of chemotherapy drugs as anti-proliferating agents, a reduction in the proliferation of 
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cells in the hippocampus provides a reasonable hypothesis to the mechanisms through 
which chemotherapy impairs memory. 
 Unfortunately, given the time constraints imposed by the deadline of this project, 
we were unable to prepare and analyze tissue for the presence of protein indicators of 
neurogenesis in the hippocampus.   However, given the results of the data from the 
myelin staining, we can make inferences as to what the hippocampal neurogenesis results 
are likely to be. Persistently low levels of myelin density 6 months following 
chemotherapy treatment suggests that the brain is still limited in its ability to produce 
normal amounts of myelin.  This must mean that the process of oligogenesis (the only 
way by which the brain can produce new myelin) must be affected some way, either 
through the actual production of new glia cells, or the successful survivability and 
integration of those produced.  In either case, it is likely that if oligogenesis is affected by 
chemotherapy, so to will neurogenesis in the hippocampus.  
  
 While many studies have investigated the impact of a variety of chemotherapy 
agents on both brain histology and behavioral measures of cognition in animals, few have 
made experimental investigations at time points considered to reflect long term or 
permanent impairment in humans.  This is one of several reasons why results from this 
study are being considered with cautious optimism; as providing potential evidence for 
the presence of well-documented, histological abnormalities in areas of the brain 
associated with learning, memory and processing speed, following chemotherapy 
administration, not only transiently, but well after the discontinuation of treatment.  
Before hard conclusions can be drawn from this study, not only will the analysis of 
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hippocampal neurogenesis need to be run, but all results will need to be substantiated 
through multiple replications.  This is particularly necessitated by the small n-values for 
each condition, and the potentially imprecise assessment and determination of tissue 
quality.  In addition, the use of nissle body staining will be necessary in determining 
identifying characteristics of oligodendrocytes in the corpus callosum. 
 Despite resource limitations and time constraints, this study was successful in 
accomplishing a majority of the goals initially presented.  Analysis of tissue stained with 
Black Gold II indicated that the administration of the chemotherapy agent 5-fluorouracil 
resulted in a decrease in myelin quality at both acute (1 day, 14 days) and extended (6 
months) time points following treatment.  In addition, results indicated that fluoxetine has 
the potential to reduce the myelin damage caused by 5-FU, shortly following the 
treatment cessation. 
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